Prof Nichola Cooper GMC 4194059 Centre for Haematology, Immunology and Inflammation, Imperial College
Du Cane Road, London W12 0HS

Current Appointments

Professor of Immune Haematology, Imperial College
Leading a basic and translational research group investigating autoimmune cytopenias

Co-Lead, Imperial College NIHR BRC Immunology
Leading translational medicine research in immune disorders across Northwest London

National Lead, NIHR Bioresources Blood Autoimmune Cytopenias
Leading genomic research into haematological autoimmunity

Director, Haematology Clinical Trials Unit
Currently running over 30 interventional and observational studies in non-malignant haematology.

Director, Immune Haematology Centre North-West London
I lead a regional clinical service for over 1000 adults, TYA, and children with immune haematology disorders.

Divisional Director of Research for Surgery and Cancer, Imperial Health Care NHS Trust
Overseeing research strategy and delivery across five hospitals

Honorary Consultant Haematologist, Imperial Health Care NHS Trust

Previous Appointments

Reader Immune Haematology, Imperial College	Aug 2020 to Aug 2023
Senior Lecturer Immune Haematology, Imperial College	Aug 2017 to Aug 2020
Consultant Haematologist Hammersmith Hospital	Jan 2009 to June 2017
Locum Consultant, Clinical Immunology RFH	May 2008 to Jan 2009
Research Fellow (postdoc), Institute of Child Health	Nov 2005 to May 2008
Haematology SpR Training, UCLH, London	Jan 1998 to Sept 2005
Research Fellow, Cornell Medical School, NYC, USA	Jan 2000 to Jan 2002

General Medical Council and Specialist Certification

CCT	Haematology	2005
GMC	Full registration 4194059	1995

Qualifications

FRCPath	London, Royal College of Pathologists	2005
MRCP/FRCP	London, Royal College of Physicians	1998/2013
MD	London University/Cornell Medical school	2005
MBBS	London University (Barts and the London)	1995
BA/MA	St John’s College, University of Cambridge	1992/6

Current Basic and Translational Research

A. *Functional genomics of immune dysregulation:*
I have established a rare disorders clinic for adults and children with immune haematology disorders (including immune thrombocytopenia, autoimmune haemolytic anaemia and other autoinflammatory disorders such as HLH), which is now the largest in the UK. I have curated a biobank with longitudinal samples over 15 years. I use this to interrogate how the immune system goes wrong. This includes using trio approach to identify novel genetic pathways in patients with complex diseases from childhood (***Nature Immunology*** **2017**); cohort approaches through BRIDGE and GEL consortiums (***Blood Advances 2025, Nature 2020, Blood 2019***). Through NIHR Bioresources we will now sequence 200 patients through the Rare Disease RNA Project.Using T cell receptor sequencing, we have described a biomarker of refractory disease (***Blood 2023***), which we are now using to better understand disease type, and disease trajectory leading to precision medicine. I am now collaborating with Novartis and Argenx to explore novel treatments to target these cells.

B. Impacts of disease:
Using MRI brain and cognitive function assessment we have identified brain pathology in ITP (***Blood 2020***), impacting on disease features (***AmJHem*** **2021**) which we are now further exploring through an NIHR funded clinical fellowship (PhD) and a BHF funded non-clinical PhD.

C. Clinical trials (CI or PI):
Anti-CD38 in ITP: phase 3 study
Ianalumab (BAFFR inhibitor): phase 3 first line & second line ITP, and AIHA, phase 2 refractory ITP (**CI**)
Iptacopan (complement inhibitor): phase 2 clinical trial ITP, CAD (**CI**)
Rilzabrutinib (BTK inhibitor): Phase 2 and 3 ITP and AIHA children and adults (***NEJM 2023, Blood 2025***) **(CI)**
Efgartigomod and rozanolixizumab (FcRninhibitor): in ITp (***BJH 2025***) (**CI**)
Eltrombopag: upfront study adults (***AJH 2024, BJH 2024***) (**CI**)
Fostamatinib (SYK inhibitor): Phase 3 RCT ITP and AIHA (***AJH 2029) (CI)***
Romiplostim and eltrombopag in children (***Blood Advances 2022***) (PI)

GRANTS LAST 10 YEARS

2026-30 Role of the microbiome in ITP – NIHR doctoral fellowship	£475K
2025-30 Exploring the genetics of ITP – MRC doctoral fellowship	£450K
2025-26: The role of LT2 on TEMRA cells in ITP: Argenx	£300K
2024-27: Exploring T cell mediated disease in ITP – Imperial Presidents PhD Michelle Tan.	£110K
2024-27: Antibody mediated causes of thrombosis in ITP – non-clinical PhD BHF	£260K
2024-25: Predicting response to B cell depletion – Novartis.	£196K
2014-26: CI and PI clinical trials immune modulators	£1.7M
2021: CoPI UKRI; Understanding platelet activation in COVID-19	£504K
2020: CI MATIS: immune modulation for COVID-19 Novartis and Rigel	£1.2M
2019: PI NIHR Fellowship Using SWI brain to assess bleeding risk in children with ITP	£450K
2018: PI Pilot study of brain Magnetic Resonance Imaging (MRI) in ITP Imperial Charity	£50K
2018-2012: CoPI Welcome Trust i4 PhD fellowship Bone Marrow Dynamics	£250K
2017-20: PI: Advances in ITP Preceptorships for European and Emerging markets	£240K
2017: PI Jon Moulton Charitable Award Manipulating T cells in ITP	£400K
2017: PI BMA award – Jon Moulton Award for ITP research – Exploring genetic components in ITP.	£50K
2016: CoPI Leuka Use of CRISPR to explore the mechanisms of BACH2	£50K
2016 - 2017: CoPI NIHR Imperial BRC Using CRISPR/Cas9 to explore dysregulation	£60K
2016- 2018: NIHR Imperial BRC Identification of autoimmune B cells in ITP	£10K

TEACHING AND SUPERVISION:
Current lab: PhD student (Platelet biology 2024 BHF); PhD student (T cells in ITP Imperial Presidential Scholarship), PhD student (genetics of immune haematology MRC); 2x clinical research fellows; Research assistant (Novartis/Argenx). Post doc (precision medicine BRC funded).
Previous:
Research Supervisor: 18 PhD and MSc students, 11 BSc students

NATIONAL AND INTERNATIONAL PROFESSIONAL LEADERSHIP ROLES
Co-founder, European Research Consortium in Immune thrombocytopenia: I coordinate a consortium of 10 researchers across 5 countries with to improve research, clinical care and education for patients with ITP

MHRA Expert Working party for Vaccine Induced Thrombosis and Thrombocytopenia 2021

Trustee and Scientific advisor, US Platelet Disorders Support Association

T**rustee and Scientific advisor, UK ITP patient support organizations**

Key Opinion Leader for Industry including Principia, Sanofi-Genzyme, UCB, Rigel, Griffols, Novartis, Amgen: I advise the design of studies for novel agents for ITP and AIHA

SELECTED INVITED SPEAKER AND CHAIR ROLES AT INTERNATIONAL MEETINGS 2024 TO 2025
Plenary speaker at EHA 2025, Association of Physicians 2025; BSH 2024, ISTH 2024.
Chair and organiser: BSH Autoimmunity session; ASH annual ITP meeting; UKITP annual meeting; ERCI annual meeting

SELECTED PUBLICATIONS – TOP 20
Citations 22428, H-index 66, i10-index 138
ORCID ID: https://orcid.org/0000-0002-9845-8292

1. Hazell L, Pillay C, Cornelius V, Phillips R, Charania A, Wason J, Cherlin S, Savic S, Whittington A, Neelakantan P, Collini P, Cook L, Willicome M, Milojkovic D, Kon OM, Youngstein T, Innes A, Thursz M, Cooke GS, Vergis N, **Cooper N**. Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic. ***BMJ Open.*** **2026** PMID: 41644167.

2. Cuker A, Stauch T, **Cooper N**, Al-Samkari H, Michel M, Ghanima W, Urban P, Fronczek J, Foster M, Weill M, Zhang L, Hou M, Zander T, Sharif A, Sun J, Nath UK, Schutgens R, Rossi E, Deleu L, Červinek L, Yoon JH, Chang H, Ruchutrakool T, Iino M, Goto T, Zaja F; VAYHIT2 Investigators. Ianalumab plus Eltrombopag in Immune Thrombocytopenia. ***N Engl J Med.*** **2025**. PMID: 41363800.

3. Audia S, **Cooper N**. T cells in ITP: Focus on T follicular helper cells and cytotoxic T cells. ***Br J Haematol.*** **2025** PMID: 41187769; PMCID: PMC12710169.

4. **Cooper N**, Jansen AJG, Bird R, Mayer J, Sholzberg M, Tarantino MD, Garg M, Ypma PF, McDonald V, Percy C, Košťál M, Goncalves I, Bogdanov LH, Gernsheimer TB, Diab R, Yao M, Daak A, Kuter DJ. Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study. ***Am J Hematol***. **2025** PMID: 39844469; PMCID: PMC11803537.

5. Joshi N, Lango-Allen H, Downes K, Simeoni I, Vladescu C, Paul D, Hart A, Ademokun C, **Cooper N**. The role of genetic sequencing in the diagnostic workup for chronic immune thrombocytopenia. ***Blood Adv.*** **2025** PMID: 39808791; PMCID: PMC11985033.

6. **Cooper N**, Ghanima W, Vianelli N, Valcárcel D, Yavaşoğlu İ, Melikyan A, Ruiz EY, Haenig J, Somenzi O, Lee J, Clark J, Zhang Y, Zaja F. Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial. ***Am J Hematol.*** **2024** Jan;99(1):57-67. doi: 10.1002/ajh.27131. Epub 2023 Nov 28. PMID: 38014779.

7. Malik A, Sayed AA, Han P, Tan MMH, Watt E, Constantinescu-Bercu A, Cocker ATH, Khoder A, Saputil RC, Thorley E, Teklemichael A, Ding Y, Hart ACJ, Zhang H, Mitchell WA, Imami N, Crawley JTB, Salles-Crawley II, Bussel JB, Zehnder JL, Adams S, Zhang BM, **Cooper N**. The role of CD8+ T-cell clones in immune thrombocytopenia. ***Blood.*** **2023** PMID: 36749920; PMCID: PMC10329190.

8. Zehnder JL, Bussel JB, **Cooper N.** The role of genetics in refractory immune thrombocytopenia. ***Br J Haematol. 2023*** PMID: 37735556.

9. Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, **Cooper N**. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. ***N Engl J Med***. **2022** PMID: 35417637.

10. Chauss D, Freiwald T, McGregor R, Yan B, Wang L, Nova-Lamperti E, Kumar D, Zhang Z, Teague H, West EE, Vannella KM, Ramos-Benitez MJ, Bibby J, Kelly A, Malik A, Freeman AF, Schwartz DM, Portilla D, Chertow DS, John S, Lavender P, Kemper C, Lombardi G, Mehta NN, **Cooper N**, Lionakis MS, Laurence A, Kazemian M, Afzali B. Autocrine vitamin D signaling switches off pro-inflammatory programs of T_H1 cells. ***Nat Immunol.*** **2022** PMID: 34764490; PMCID: PMC7612139.

11. Malik, M Toth EN, Teng MS, Hurst, J, Watt E, Wise L, Kent N, Bartram J, Grandjean L, Dominguez-Villar M, Adams S, **Cooper N** Distorted TCR repertoires define multisystem inflammatory syndrome in children with COVID-19 ***PLoS 1*** **Oct 2022**

12. Bradbury CA, Pell J, Hill Q, Bagot C, **Cooper N**, Ingram J, Breheny K, Kandiyali R, Rayment R, Evans G, Talks K, Thomas I, Greenwood R. Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia. ***N Engl J Med.*** **2021** PMID: 34469646.

13. Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, **Cooper N**, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Malhotra A. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. ***N Engl J Med.*** **2021**. PMID: 33631066; PMCID: PMC7953459.

14. Bye AP, Hoepel W, Mitchell JL, Jégouic S, Loureiro S, Sage T, Vidarsson G, Nouta J, Wuhrer M, de Taeye S, van Gils M, Kriek N, **Cooper N**, Jones I, den Dunnen J, Gibbins JM. Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets. ***Blood.*** **2021** PMID: 34315173; PMCID: PMC8321687.

15. **Cooper N**, Morrison MA, Vladescu C, Hart ACJ, Paul D, Malik A, Young T, Luqmani A, Atta M, Sharp DJ, Bussel JB, Waldman AD. Identification of occult cerebral microbleeds in adults with immune thrombocytopenia. ***Blood.*** **2020** PMID: 32750707; PMCID: PMC7751366.

16. Thaventhiran JED, Lango Allen H, Burren OS, Rae W, Greene D, Staples E, Zhang Z, Farmery JHR, Simeoni I, Rivers E, Maimaris J, Penkett CJ, Stephens J, Deevi SVV, Sanchis-Juan A, Gleadall NS, Thomas MJ, Sargur RB, Gordins P, Baxendale HE, Brown M, Tuijnenburg P, Worth A, Hanson S, Linger RJ, Buckland MS, Rayner-Matthews PJ, Gilmour KC, Samarghitean C, Seneviratne SL, Sansom DM, Lynch AG, Megy K, Ellinghaus E, Ellinghaus D, Jorgensen SF, Karlsen TH, Stirrups KE, Cutler AJ, Kumararatne DS, Chandra A, Edgar JDM, Herwadkar A, **Cooper N**, Grigoriadou S, Huissoon AP, Goddard S, Jolles S, Schuetz C, Boschann F; Primary Immunodeficiency Consortium for the NIHR Bioresource; Lyons PA, Hurles ME, Savic S, Burns SO, Kuijpers TW, Turro E, Ouwehand WH, Thrasher AJ, Smith KGC. Publisher Correction: Whole-genome sequencing of a sporadic primary immunodeficiency cohort. ***Nature.*** **2020** PMID: 32678341.

17. Thaventhiran JED, Lango Allen H, Burren OS, Rae W, Greene D, Staples E, Zhang Z, Farmery JHR, Simeoni I, Rivers E, Maimaris J, Penkett CJ, Stephens J, Deevi SVV, Sanchis-Juan A, Gleadall NS, Thomas MJ, Sargur

RB, Gordins P, Baxendale HE, Brown M, Tuijnenburg P, Worth A, Hanson S, Linger RJ, Buckland MS, Rayner-Matthews PJ, Gilmour KC, Samarghitean C, Seneviratne SL, Sansom DM, Lynch AG, Megy K, Ellinghaus E, Ellinghaus D, Jorgensen SF, Karlsen TH, Stirrups KE, Cutler AJ, Kumararatne DS, Chandra A, Edgar JDM, Herwadkar A, **Cooper N**, Grigoriadou S, Huissoon AP, Goddard S, Jolles S, Schuetz C, Boschann F; Primary Immunodeficiency Consortium for the NIHR Bioresource; Lyons PA, Hurles ME, Savic S, Burns SO, Kuijpers TW, Turro E, Ouwehand WH, Thrasher AJ, Smith KGC. Whole-genome sequencing of a sporadic primary immunodeficiency cohort. ***Nature*. 2020** PMID: 32499645; PMCID: PMC7334047.

18. **Cooper N**, Ghanima W. Immune Thrombocytopenia. ***N Engl J Med*.** **2019** PMID: 31483965.

19. Povoleri GAM, Nova-Lamperti E, Scottà C, Fanelli G, Chen YC, Becker PD, Boardman D, Costantini B, Romano M, Pavlidis P, McGregor R, Pantazi E, Chauss D, Sun HW, Shih HY, Cousins DJ, **Cooper N**, Powell N, Kemper C, Pirooznia M, Laurence A, Kordasti S, Kazemian M, Lombardi G, Afzali B. Human retinoic acid-regulated CD161^{+} regulatory T cells support wound repair in intestinal mucosa. ***Nat Immunol*.** **2018** PMID: 30397350; PMCID: PMC6474659.

20. Afzali B, Grönholm J, Vandrovcova J, O'Brien C, Sun HW, Vanderleyden I, Davis FP, Khoder A, Zhang Y, Hegazy AN, Villarino AV, Palmer IW, Kaufman J, Watts NR, Kazemian M, Kamenyeva O, Keith J, Sayed A, Kasperaviciute D, Mueller M, Hughes JD, Fuss IJ, Sadiyah MF, Montgomery-Recht K, McElwee J, Restifo NP, Strober W, Linterman MA, Wingfield PT, Uhlig HH, Roychoudhuri R, Aitman TJ, Kelleher P, Lenardo MJ, O'Shea JJ, **Cooper N** (**joint corresponding author**), Laurence ADJ. BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. ***Nat Immunol*.** **2017** PMID: 28530713; PMCID: PMC5593426.